Clinical trials for Non-Hodgkin lymphoma
24 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPHASE1, PHASE2NCT07222631SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomasUniversity of California, San Diego · PI: Peter Vu, MD
- RECRUITINGNCT07313943PAX5-NEGATIVE HODGKIN-LIKE LYMPHOMAS: A DIAGNOSTIC CHALLANGEIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGPhase 2NCT07283822Amping up With PemJAKSeda S. Tolu · PI: Seda Tolu, MD
- RECRUITINGN/ANCT06923397Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND TrialDana-Farber Cancer Institute · PI: Christina Dieli-Conwright, MD, PhD
- RECRUITINGPhase 2NCT06854003BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell LymphomaChristine Ryan · PI: Christine Ryan, MD
- ACTIVE NOT RECRUITINGPhase 1NCT06622226A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin LymphomaOno Pharmaceutical Co. Ltd · PI: Project Leader
- RECRUITINGPhase 1NCT06522932PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T TherapyMichael Randall · PI: Randall Michael, MD
- RECRUITINGPhase 1NCT06420089CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)Vittoria Biotherapeutics
- RECRUITINGPhase 1NCT06484985Study of AXT-1003 in Subjects With Advanced Malignant Tumors.Axter Therapeutics (Beijing) Co., Ltd · PI: Qian Gao
- RECRUITINGPhase 2NCT05583071Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSLUniversity of Cologne
- RECRUITINGN/ANCT06004011AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW)Implenomics
- RECRUITINGPhase 1NCT05967416Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's LymphomaSIRPant Immunotherapeutics, Inc. · PI: Jelle Kijlstra, MD, MBA
- RECRUITINGPHASE1, PHASE2NCT06119685IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic CancersIndapta Therapeutics, INC. · PI: Indapta Therapeutics, Inc.
- ACTIVE NOT RECRUITINGPhase 1NCT05878184Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)Sana Biotechnology · PI: John Gerecitano, MD, PhD
- RECRUITINGN/ANCT05839210Lifestyle Intervention of Food and Exercise for Lymphoma SurvivorsUniversity of Miami · PI: Tracy E Crane, Phd, RDN
- RECRUITINGN/ANCT05595577Improving Exercise Capacity With a Tailored Physical Activity InterventionWake Forest University Health Sciences · PI: William Hundley, MD
- ACTIVE NOT RECRUITINGPhase 2NCT04827862RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose RadiotherapyAbramson Cancer Center at Penn Medicine · PI: Michael LaRiviere, MD
- ACTIVE NOT RECRUITINGPhase 1NCT05053659Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin LymphomaPaolo Caimi, MD · PI: Paolo Caimi, MD
- RECRUITINGPhase 2NCT05283720A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin LymphomaGenmab · PI: ABBVIE INC.
- RECRUITINGPHASE1, PHASE2NCT06021678Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin LymphomaGuangzhou Excelmab Inc. · PI: Junyuan Qi, MD, PHD
- RECRUITINGPhase 1NCT02917083CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)Baylor College of Medicine · PI: Carlos A Ramos, MD
- RECRUITINGPhase 2NCT03125642Auto Stem Cell Transplant for Lymphoma PatientsMasonic Cancer Center, University of Minnesota · PI: Veronika Bachanova, MD
- RECRUITINGPhase 2NCT02393157Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHLNew York Medical College · PI: Mitchell Cairo, MD
- ACTIVE NOT RECRUITINGPhase 1NCT02287311Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)Baylor College of Medicine · PI: Rayne H Rouce, MD